Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic Carcinoma|Triple-Negative Invasive Breast Carcinoma
Interventions: BIOLOGICAL: anti-MUC1 CAR T Cells
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators: The First People's Hospital of Hefei|Hefei Binhu Hospital